Safety and Efficacy of Oral HX9428 Tablets in Subjects With Wet Age-related Macular Degeneration (wAMD)

Not Applicable

Recruiting

• Conditions: Wet Age-related Macular Degeneration (AMD)
• Interventions: Drug: HX9428 tablet

• Registration Number: NCT07185841
• Lead Sponsor: Fujian Haixi Pharmaceuticals Co., Ltd.

Brief Summary

This study will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of Oral HX9428 tablets in patients with wet age-related macular degeneration(wAMD)

Detailed Description

This is a Multicenter, Open-label, Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral HX9428 tablets in Subjects with Wet Age-related Macular Degeneration (wAMD). The study consists of 2 segments: Phase I and Phase II. Phase I will evaluate the safety and tolerability of HX9428 administered as single and multiple oral doses; dose escalation will follow a 3 + 3 design with overdose control. If evidence of efficacy is observed at any dose level during Phase I, a parallel Phase II study may be initiated while dose-escalation in Phase I continues. In Phase II, the daily dose of HX9428 will not exceed the Maximum Tolerated Dose (MTD) established in Phase I; dosing frequency will be once daily (QD) or every other day (QOD).The primary objective of Phase II is to assess the preliminary efficacy of HX9428 tablets under these regimens.

Study Timeline

• Study Start: 2025-07-01
• Status Verified: 2025-09
• Study First Submitted: 2025-09-15
• Study First Submitted QC: 2025-09-15
• Last Update Submitted: 2025-09-15
• Study First Posted: 2025-09-22
• Last Update Posted: 2025-09-22
• Primary Completion: 2028-07-01
• Study Completion: 2029-01-07

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 198

Inclusion Criteria

• Participants must meet the following criteria for study entry:

  1. Age ≥50 years and ≤80 years (Phase I), Age ≥50 years and ≤85 years (Phase II) at the time of signing informed consent, male or female;
  2. Active choroidal neovascularization (CNV) secondary to AMD, as evidenced on fluorescein fundus angiography (FFA) and optical coherence tomography (OCT) (Active CNV is defined as the presence of subretinal or intraretinal fluid or leakage); A total lesion size of ≤12 disc areas on FFA ;
  3. Treatment-naive , or previous anti-VEGF treatment that was effective and discontinued for more than 3 months, with OCT evidence of subretinal fluid or cystoid macular edema;
  4. ETDRS BCVA 19 to 78 letters in the study eyes( corresponding to a Snellen equivalent of approximately 20/32 to 20/400) ;
  5. Other protocol-specified inclusion criteria may apply

Exclusion Criteria

• Subjects who meet any of the following criteria will be excluded from this study:

  1. Subjects diagnosed with polypoidal choroidal vasculopathy by Indocyanine Green(ICG) angiography who are at high risk of massive hemorrhage;
  2. On FFA/CFP: subretinal hemorrhage of >50 % of the total lesion area or that involves the fovea; fibrosis or atrophy of >50 % of the total lesion area or that involves the fovea;
  3. CNV due to causes other than AMD;
  4. Any condition in the study eye that could compromise best-corrected visual acuity;
  5. Active ocular inflammation or infection in either eye or a history of idiopathic or autoimmune-related uveitis;
  6. Refractive error exceeding -6.00 D spherical equivalent;
  7. Ocular surgery performed in the study eye within 90 days before screening;
  8. Previous treatment with photodynamic therapy (within 120 days of screening), external-beam radiotherapy, macular laser photocoagulation, macular surgery, or transpupillary thermotherapy;
  9. Systemic anti-VEGF therapy administered within 90 days before the first dose;
  10. Pregnant or lactating women;
  11. Known hypersensitivity or contraindication to any study-related procedure drugs;
  12. History of severe cardiac disease, symptomatic congestive heart failure, unstable angina, acute coronary syndrome, myocardial infarction, coronary revascularization, thrombotic event, or bleeding episode within 6 months prior to the start of study drug, uncontrolled hypertension (systolic blood pressure> 150 mmHg and/or diastolic blood pressure > 100 mmHg on optimal medical therapy), or ventricular arrhythmia requiring ongoing treatment;
  13. Stroke within 12 months or transient ischemic attack within 6 months of enrolment；
  14. Poorly controlled diabetes (HbA1c ≥ 12 %);
  15. Other protocol-specified exclusion criteria may apply.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
HX9428 tablet	HX9428 tablet	Escalating dose of HX9428 tablet starting at 5mg once a day.

Primary Outcome Measures

Name	Time	Method
Phase I : Dose-Limiting Toxicity (DLT)	Week 4	Dose-limiting toxicity (DLT) refers to a drug-related toxicity during treatment with the drug, the severity of which is clinically unacceptable, limiting the further escalation of drug dose
Phase II： Mean change of letters from baseline in BCVA (Best Corrected Visual Acuity)	week 25	Visual function was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better vision

Secondary Outcome Measures

Name	Time	Method
Mean change from baseline in Central Subfield Thickness（CST）	week 25	Evaluated by Optical Coherence Tomography (OCT). The higher values means worse outcome.
Proportion of patients gaining at least 15/10/5 letters from baseline in the BCVA	Week 25	Visual function was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better vision.
Mean change from baseline in the total area of CNV and the total area of fluorescein leakage	Week 25	Evaluated by Fundus Fluorescein Angiography (FFA)
Pharmacokinetic (PK) profile	Week 4	Study the change of HX9428 drug concentration in the blood

Trial Locations

Locations (1)

Beijing Hospital; 🇨🇳 Beijing, China